Novartis AG (ADR) (NVS) was Initiated by Chardan Capital Markets to “Buy” and the brokerage firm has set the Price Target at $95. Chardan Capital Markets advised their investors in a research report released on Sep 20, 2016.
On the company’s financial health, Novartis AG (ADR) reported $1.23 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.18. The company had revenue of $12470.00 million for the quarter, compared to analysts expectations of $12206.45 million. The company’s revenue was down -1.8 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.27 EPS.
Novartis AG (ADR) closed down -0.54 points or -0.68% at $79.34 with 1,111,327 shares getting traded on Friday. Post opening the session at $79.55, the shares hit an intraday low of $79.13 and an intraday high of $79.64 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Novartis AG is a holding company that through its subsidiaries is engaged in development manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines eye care generic pharmaceuticals preventive vaccines and over-the-counter (OTC) products. The Company’s segments include Pharmaceuticals which include patent-protected prescription medicines; Alcon which include surgical ophthalmic pharmaceutical and vision care products; Sandoz which include generic pharmaceuticals and Consumer Health which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia Exjade Galvus Exforge and Voltaren among others. Its Sandoz products include Valsartan (Diovan) Cyclophosphamide injection and AirFluSal Forspiro among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.